JP2019522973A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019522973A5 JP2019522973A5 JP2018567062A JP2018567062A JP2019522973A5 JP 2019522973 A5 JP2019522973 A5 JP 2019522973A5 JP 2018567062 A JP2018567062 A JP 2018567062A JP 2018567062 A JP2018567062 A JP 2018567062A JP 2019522973 A5 JP2019522973 A5 JP 2019522973A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen recognition
- domain
- recognition domain
- receptor
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 45
- 102000036639 antigens Human genes 0.000 claims 45
- 108091007433 antigens Proteins 0.000 claims 45
- 210000004027 cell Anatomy 0.000 claims 34
- -1 NY-ES0-1 Proteins 0.000 claims 20
- 102100033726 Tumor necrosis factor receptor superfamily member 17 Human genes 0.000 claims 18
- 229920001184 polypeptide Polymers 0.000 claims 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims 18
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 15
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 15
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 claims 14
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 claims 14
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 12
- 102000010956 Glypican Human genes 0.000 claims 12
- 108050001154 Glypican Proteins 0.000 claims 12
- 108050007237 Glypican-3 Proteins 0.000 claims 12
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims 12
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims 12
- 230000000139 costimulatory effect Effects 0.000 claims 12
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 11
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 11
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 9
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 9
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims 9
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 9
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims 9
- 101000801255 Homo sapiens Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 claims 9
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims 9
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 9
- 102100035721 Syndecan-1 Human genes 0.000 claims 9
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 8
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 8
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 8
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 8
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims 7
- 101710178300 Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims 7
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims 6
- 102100022749 Aminopeptidase N Human genes 0.000 claims 6
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims 6
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims 6
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 claims 6
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims 6
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 claims 6
- 101001015004 Homo sapiens Integrin beta-3 Proteins 0.000 claims 6
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 claims 6
- 101001008874 Homo sapiens Mast/stem cell growth factor receptor Kit Proteins 0.000 claims 6
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims 6
- 102100025306 Integrin alpha-IIb Human genes 0.000 claims 6
- 102100032999 Integrin beta-3 Human genes 0.000 claims 6
- 108010038501 Interleukin-6 Receptors Proteins 0.000 claims 6
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims 6
- 102100025136 Macrosialin Human genes 0.000 claims 6
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 claims 6
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims 6
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 claims 6
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 6
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 claims 6
- 101710181056 Tumor necrosis factor ligand superfamily member 13B Proteins 0.000 claims 6
- 230000011664 signaling Effects 0.000 claims 6
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 claims 5
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims 5
- 101001005269 Arabidopsis thaliana Ceramide synthase 1 LOH3 Proteins 0.000 claims 4
- 101001005312 Arabidopsis thaliana Ceramide synthase LOH1 Proteins 0.000 claims 4
- 102100028801 Calsyntenin-1 Human genes 0.000 claims 4
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 4
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 4
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims 4
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 4
- 101000668858 Spinacia oleracea 30S ribosomal protein S1, chloroplastic Proteins 0.000 claims 4
- 101000898746 Streptomyces clavuligerus Clavaminate synthase 1 Proteins 0.000 claims 4
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000002062 proliferating effect Effects 0.000 claims 4
- 102000016605 B-Cell Activating Factor Human genes 0.000 claims 3
- 108010028006 B-Cell Activating Factor Proteins 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003623 enhancer Substances 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 210000000581 natural killer T-cell Anatomy 0.000 claims 2
- 210000000822 natural killer cell Anatomy 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 1
- 108010083359 Antigen Receptors Proteins 0.000 claims 1
- 102000006306 Antigen Receptors Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims 1
- 101000831616 Homo sapiens Protachykinin-1 Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 206010020631 Hypergammaglobulinaemia benign monoclonal Diseases 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims 1
- 208000001715 Osteoblastoma Diseases 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 102100024304 Protachykinin-1 Human genes 0.000 claims 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 208000025750 heavy chain disease Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 208000031223 plasma cell leukemia Diseases 0.000 claims 1
- 208000010626 plasma cell neoplasm Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2016/039306 WO2016210293A1 (en) | 2015-06-25 | 2016-06-24 | CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF |
| USPCT/US2016/039306 | 2016-06-24 | ||
| US201662369004P | 2016-07-29 | 2016-07-29 | |
| US62/369,004 | 2016-07-29 | ||
| PCT/US2016/068349 WO2017222593A1 (en) | 2016-06-24 | 2016-12-22 | Chimeric antigen receptors (cars), compositions and methods thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019522973A JP2019522973A (ja) | 2019-08-22 |
| JP2019522973A5 true JP2019522973A5 (cg-RX-API-DMAC7.html) | 2020-02-06 |
| JP7114490B2 JP7114490B2 (ja) | 2022-08-08 |
Family
ID=60783276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018567062A Active JP7114490B2 (ja) | 2016-06-24 | 2016-12-22 | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US20200283534A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3474867A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7114490B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN109562126A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3029197A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017222593A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (132)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4400516A1 (en) | 2014-12-15 | 2024-07-17 | The Regents of the University of California | Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20 |
| JP6895380B2 (ja) | 2015-02-06 | 2021-06-30 | ナショナル ユニバーシティ オブ シンガポール | 治療免疫細胞の有効性を改良するための方法 |
| US20220348633A1 (en) * | 2015-06-25 | 2022-11-03 | Icell Gene Therapeutics Llc | COMPOUND CHIMERIC ANTIGEN RECEPTOR (cCAR) TARGETING MULTIPLE ANTIGENS, COMPOSITIONS AND METHOD OF USE THEREOF |
| TW202444897A (zh) * | 2015-06-25 | 2024-11-16 | 美商生物細胞基因治療有限公司 | 嵌合抗原受體(car)、組合物及其使用方法 |
| CN108472365A (zh) | 2015-10-30 | 2018-08-31 | 艾丽塔生物治疗剂公司 | 用于肿瘤转导的组合物和方法 |
| CA3002674A1 (en) * | 2015-10-30 | 2017-05-04 | Aleta Biotherapeutics Inc. | Compositions and methods for treatment of cancer |
| US11384156B2 (en) * | 2016-07-25 | 2022-07-12 | The Nemours Foundation | Adoptive T-cell therapy using EMPD-specific chimeric antigen receptors for treating IgE-mediated allergic diseases |
| CA3032429A1 (en) | 2016-08-03 | 2018-02-08 | Washington University | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors |
| WO2018042385A2 (en) | 2016-09-02 | 2018-03-08 | The Regents Of The University Of California | Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments |
| JP2019535262A (ja) * | 2016-11-11 | 2019-12-12 | オートラス リミテッド | キメラ抗原受容体 |
| CA3061898A1 (en) | 2016-12-28 | 2019-10-29 | Green Cross Lab Cell Corporation | Chimeric antigen receptor and natural killer cells expressing same |
| EP3568466A4 (en) | 2017-01-10 | 2020-07-15 | The General Hospital Corporation | TARGETED T CELLS WITH CYTOTOXICITY TO IMMUNOSUPPRESSIVE CELLS |
| EP3568406A4 (en) * | 2017-01-10 | 2020-10-21 | The General Hospital Corporation | T LYMPHOCYTES EXPRESSING A CHEMERICAL ANTIGENIC RECEPTOR |
| US11975029B2 (en) | 2017-02-28 | 2024-05-07 | Vor Biopharma Inc. | Compositions and methods for inhibition of lineage specific proteins |
| AU2018251898A1 (en) | 2017-04-13 | 2019-10-31 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| WO2018191748A1 (en) * | 2017-04-14 | 2018-10-18 | The General Hospital Corporation | Chimeric antigen receptor t cells targeting the tumor microenvironment |
| AU2018256436B2 (en) * | 2017-04-19 | 2024-12-05 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| CN110914289B (zh) | 2017-05-12 | 2024-05-14 | 克里斯珀医疗股份公司 | 用于工程化细胞的材料和方法及其在免疫肿瘤学中的用途 |
| US12275787B2 (en) | 2017-06-21 | 2025-04-15 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (CARs), compositions and methods thereof |
| AU2018298060B2 (en) | 2017-07-03 | 2021-02-25 | Torque Therapeutics, Inc. | Immunostimulatory fusion molecules and uses thereof |
| CA3071624A1 (en) | 2017-07-31 | 2019-02-07 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-cd19/cd20 immunotherapy |
| US20190038733A1 (en) | 2017-08-10 | 2019-02-07 | National University Of Singapore | T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof |
| WO2019084248A1 (en) | 2017-10-25 | 2019-05-02 | Actinium Pharmaceuticals, Inc. | METHODS OF ANTI-CD45-BASED LYMPHODEPPLICATION AND USES THEREOF IN COMBINATION WITH ACT-BASED ANTICANCER THERAPIES |
| MA49911A (fr) | 2017-11-01 | 2020-06-24 | Juno Therapeutics Inc | Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b |
| BR112020008638A2 (pt) | 2017-11-01 | 2020-10-20 | Juno Therapeutics Inc | receptores de antígenos quiméricos específicos para antígenos de maturação de células b (bcma) |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| US12116417B2 (en) | 2017-11-14 | 2024-10-15 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| WO2019106592A2 (en) * | 2017-11-30 | 2019-06-06 | Grifols Diagnostic Solutions Inc. | Immunoassays and engineered proteins for monitoring antibody treatments to the immune checkpoint inhibitors pd1 and pd-l1 |
| US20210054086A1 (en) * | 2018-01-10 | 2021-02-25 | The General Hospital Corporation | Immune cells expressing a chimeric antigen receptor |
| CN108314738B (zh) * | 2018-01-29 | 2020-09-08 | 山东兴瑞生物科技有限公司 | 一种共表达细胞因子il-21的双特异性嵌合抗原受体、质粒、cik细胞及mm病应用 |
| JP7360174B2 (ja) | 2018-02-09 | 2023-10-12 | ナショナル ユニヴァーシティー オブ シンガポール | ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用 |
| WO2019160956A1 (en) * | 2018-02-13 | 2019-08-22 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
| CN112041432A (zh) * | 2018-02-15 | 2020-12-04 | 纪念斯隆-凯特林癌症中心 | Foxp3靶向剂组合物以及用于过继细胞疗法的使用方法 |
| EP3755349A4 (en) | 2018-02-21 | 2021-11-17 | Board of Regents, The University of Texas System | PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES |
| JP7462578B2 (ja) * | 2018-03-15 | 2024-04-05 | ファンダメンタル ソリューションズ コーポレーション | プログラム可能な免疫細胞受容体複合体システム |
| EP3773657A4 (en) * | 2018-03-26 | 2021-12-08 | Altor Bioscience LLC | ANTI-PDL1, IL-15 AND TGF BETA RECEPTOR COMBINATION MOLECULES |
| JP7334985B2 (ja) | 2018-04-02 | 2023-08-29 | ナショナル ユニヴァーシティー オブ シンガポール | 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和 |
| US20210145881A1 (en) * | 2018-04-09 | 2021-05-20 | Mayo Foundation For Medical Education And Research | Methods and materials for treating graft-versus-host disease |
| EP3774872A1 (en) * | 2018-04-12 | 2021-02-17 | Kite Pharma, Inc. | Chimeric receptor t cell treatment using characteristics of the tumor microenvironment |
| EP3561053A1 (en) * | 2018-04-26 | 2019-10-30 | Baylor College of Medicine | Immune effector cells and molecular adaptors with an antigen cytokine complex for effective cancer immunotherapy |
| EP3784256A4 (en) * | 2018-04-27 | 2022-06-29 | Baylor College of Medicine | Car t cells with one or more interleukins |
| US12473342B2 (en) | 2018-04-27 | 2025-11-18 | The Trustees Of The University Of Pennsylvania | Chimeric antigen receptor T regulatory cells for the treatment of atherosclerosis |
| CN110468105B (zh) * | 2018-05-09 | 2024-03-22 | 恺兴生命科技(上海)有限公司 | 表达il-18r结合蛋白的免疫效应细胞 |
| PE20210666A1 (es) | 2018-05-11 | 2021-03-31 | Crispr Therapeutics Ag | Metodos y composiciones para tratar el cancer |
| US20210230289A1 (en) * | 2018-06-12 | 2021-07-29 | The Regents Of The University Of California | Single-chain bispecific chimeric antigen receptors for the treatment of cancer |
| AU2019287720B2 (en) | 2018-06-14 | 2025-08-28 | Regeneron Pharmaceuticals, Inc. | CD79A chimeric antigen receptors |
| WO2019246593A2 (en) * | 2018-06-22 | 2019-12-26 | Fred Hutchinson Cancer Research Center | Compositions and methods to target cll-1 and cd123 for the treatment of acute myeloid leukemia and related disorders |
| WO2020009868A1 (en) | 2018-07-03 | 2020-01-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-slamf7 chimeric antigen receptors |
| CN108864307A (zh) * | 2018-07-23 | 2018-11-23 | 北京多赢时代科技有限公司 | 信号肽优化靶向cd19的嵌合抗原受体、表达该嵌合抗原受体的t细胞及制备方法和应用 |
| US20210079111A1 (en) * | 2018-08-04 | 2021-03-18 | AbCyte Therapeutics Inc. | Cd19-cd20 bispecific and dual passway car-t and methods for use thereof |
| CN110862967A (zh) * | 2018-08-27 | 2020-03-06 | 天津天锐生物科技有限公司 | 一种不依赖细胞因子培养的自然杀伤细胞系silk-nk |
| CN113423725A (zh) | 2018-08-28 | 2021-09-21 | Vor生物制药股份有限公司 | 遗传工程化造血干细胞及其用途 |
| EP3845654A4 (en) * | 2018-08-31 | 2022-05-11 | Noile-Immune Biotech, Inc. | Car-expressing t cells and car expression vector |
| WO2020051374A1 (en) * | 2018-09-05 | 2020-03-12 | Poseida Therapeutics, Inc. | Allogeneic cell compositions and methods of use |
| CN110950965B (zh) * | 2018-09-26 | 2021-10-15 | 重庆精准生物技术有限公司 | 抗人cd123的嵌合抗原受体及其应用 |
| WO2020061796A1 (en) * | 2018-09-26 | 2020-04-02 | Hrain Biotechnology Co., Ltd. | Bcma-and-cd19-targeting chimeric antigen receptor and uses thereof |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CN113286874A (zh) * | 2018-10-12 | 2021-08-20 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(CARs)组合物及使用方法 |
| JP2022512766A (ja) * | 2018-10-17 | 2022-02-07 | センティ バイオサイエンシズ インコーポレイテッド | 組み合わせがん免疫療法 |
| US11419898B2 (en) | 2018-10-17 | 2022-08-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| WO2020092736A1 (en) | 2018-10-31 | 2020-05-07 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| US12264189B2 (en) | 2018-10-31 | 2025-04-01 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| JP2022512968A (ja) | 2018-11-01 | 2022-02-07 | グレイセル・バイオテクノロジーズ（シャンハイ）カンパニー・リミテッド | Ｔ細胞操作のための組成物および方法 |
| SG11202104188VA (en) | 2018-11-01 | 2021-05-28 | Juno Therapeutics Inc | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen |
| TW202021981A (zh) * | 2018-11-01 | 2020-06-16 | 美商奇諾治療有限公司 | G蛋白偶合受體c類第5群成員d（gprc5d）特異性嵌合抗原受體 |
| WO2020113054A1 (en) | 2018-11-30 | 2020-06-04 | Mustang Bio, Inc. | Methods of treatment using decitabine and a cd123-targeted therapy |
| US20220047636A1 (en) * | 2018-12-13 | 2022-02-17 | The General Hospital Corporation | Chimeric antigen receptors targeting cd79b and cd19 |
| EP3889263A4 (en) | 2018-12-24 | 2022-08-17 | Haidong Huang | GENE CODING FOR MUTANT HUMAN 2IG-B7-H3 PROTEIN, RECOMBINANT VECTOR, HOST CELL WITH IT, PHARMACEUTICAL COMPOSITION AND USE THEREOF |
| JP2022524178A (ja) * | 2019-01-07 | 2022-04-28 | セルリス パルティシパソエス リミターダ | タンデム受容体ｃａｒにおける二重特異性と腫瘍マイクロ環境を変調する方法 |
| CA3128518A1 (en) * | 2019-02-01 | 2020-08-06 | Actinium Pharmaceuticals, Inc. | Molecules and their derivatives directed against cd45 |
| CN118546959A (zh) | 2019-03-05 | 2024-08-27 | 恩卡尔塔公司 | Cd19定向性嵌合抗原受体及其在免疫疗法中的用途 |
| KR102298640B1 (ko) * | 2019-03-28 | 2021-09-07 | 한국생명공학연구원 | Car 유전자가 도입된 nk 세포의 제조방법 및 그의 용도 |
| WO2020210719A1 (en) * | 2019-04-10 | 2020-10-15 | Elevatebio Management, Inc. | Flt3-specific chimeric antigen receptors and methods of using the same |
| CN110055281B (zh) * | 2019-04-25 | 2020-09-01 | 山东大学第二医院 | 一种用于制备car-t的慢病毒载体及其构建方法和应用 |
| EA202192975A1 (ru) | 2019-04-30 | 2022-02-01 | Криспр Терапьютикс Аг | Аллогенная клеточная терапия b-клеточных злокачественных новообразований с применением генетически сконструированных т-клеток, нацеливающихся на cd19 |
| SG11202111130SA (en) * | 2019-04-30 | 2021-11-29 | Senti Biosciences Inc | Chimeric receptors and methods of use thereof |
| KR20220016475A (ko) * | 2019-05-01 | 2022-02-09 | 주노 쎄러퓨티크스 인코퍼레이티드 | 변형된 ｔｇｆｂｒ2 유전자 좌에서 재조합 수용체를 발현하는 세포, 관련 폴리뉴클레오티드 및 방법 |
| EP3747904A1 (en) * | 2019-06-03 | 2020-12-09 | Universität Regensburg | Cd25-specific chimeric antigen receptors and their uses |
| US20200384029A1 (en) * | 2019-06-07 | 2020-12-10 | The Trustees Of The University Of Pennsylvania | Dual car expressing t cells individually linked to cd28 and 4-1bb |
| AU2020291922A1 (en) * | 2019-06-14 | 2022-02-10 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for treating cancer |
| US20230181027A1 (en) * | 2019-06-28 | 2023-06-15 | Mayo Foundation For Medical Education And Research | Methods and materials for treating neuromyelitis optica spectrum diseases |
| CN112204135A (zh) * | 2019-07-06 | 2021-01-08 | 苏州克睿基因生物科技有限公司 | 一种表达cd3抗体受体复合物的免疫细胞及其用途 |
| US12428476B2 (en) | 2019-07-11 | 2025-09-30 | Valkyr, Inc. | System and methods relating to chimeric autoantibody receptors |
| CN114286683B (zh) * | 2019-07-17 | 2024-10-01 | 新加坡国立大学 | 由免疫细胞合成和分泌的功能性结合物 |
| CN110452294B (zh) * | 2019-08-06 | 2020-08-07 | 复旦大学 | 五种铰链区及其嵌合抗原受体和免疫细胞 |
| US20220324987A1 (en) * | 2019-08-28 | 2022-10-13 | Montefiore Medical Center | Cd25 chimeric antigen receptors and uses thereof |
| WO2021057906A1 (zh) * | 2019-09-25 | 2021-04-01 | 科济生物医药（上海）有限公司 | 表达il-15的免疫效应细胞 |
| WO2021064718A1 (en) * | 2019-10-01 | 2021-04-08 | Case Western Reserve University | Targeting b cell activating factor receptor (baff-r) using ligand-based chimeric antigen receptor (car)-t cells |
| AU2020361683A1 (en) | 2019-10-11 | 2022-05-19 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting CD13 and TIM-3 with CAR T cells to treat acute myeloid leukemia |
| TWI717880B (zh) | 2019-10-24 | 2021-02-01 | 中國醫藥大學附設醫院 | Hla-g特異性嵌合抗原受體、核酸、hla-g特異性嵌合抗原受體表達質體、表達hla-g特異性嵌合抗原受體細胞、其用途以及用於治療癌症之醫藥組合物 |
| CN115925976A (zh) * | 2019-11-21 | 2023-04-07 | 博生吉医药科技(苏州)有限公司 | Cd7-car-t细胞及其制备和应用 |
| WO2021113853A1 (en) * | 2019-12-05 | 2021-06-10 | Vycellix, Inc. | Modulators of the immune escape mechanism for universal cell therapy |
| CN114761038A (zh) * | 2020-02-24 | 2022-07-15 | 凯斯西储大学 | 使用基于配体的嵌合抗原受体(car)-t细胞靶向b细胞激活因子受体(baff-r) |
| AU2021225949A1 (en) * | 2020-02-27 | 2022-09-15 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| WO2021207171A1 (en) * | 2020-04-06 | 2021-10-14 | St. Jude Children's Research Hospital, Inc. | B7-h3 chimeric antigen receptors |
| CN111411085A (zh) * | 2020-04-10 | 2020-07-14 | 格源致善(上海)生物科技有限公司 | 一种嵌合抗原受体t细胞及其应用 |
| CN113527507A (zh) * | 2020-04-16 | 2021-10-22 | 上海赛比曼生物科技有限公司 | 靶向cd22的嵌合抗原受体及其制法和应用 |
| WO2021223705A1 (en) * | 2020-05-06 | 2021-11-11 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for t cell engineering |
| US12202882B2 (en) | 2020-05-08 | 2025-01-21 | Alpine Immune Sciences, Inc. | APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof |
| US20230338531A1 (en) * | 2020-08-20 | 2023-10-26 | City Of Hope | Compositions and uses of cd45 targeted chimeric antigen receptor modified t cells |
| US20230321242A1 (en) * | 2020-08-24 | 2023-10-12 | Charité - Universitätsmedizin Berlin | Chimeric antigen receptor (car)-expressing cells recognizing cea |
| TW202216990A (zh) * | 2020-09-08 | 2022-05-01 | 中國大陸商亘喜生物科技（上海）有限公司 | 用於ｔ細胞工程化的組合物和方法 |
| WO2022061837A1 (en) * | 2020-09-27 | 2022-03-31 | Jiangsu Cell Tech Medical Research Institute Co., Ltd. | Fibronectin extra domain b (edb) -specific car-t for cancer |
| CN116783283A (zh) * | 2020-11-13 | 2023-09-19 | Gpb科学有限公司 | 产生具有增加的核酸摄取的细胞群体的方法 |
| US11591381B2 (en) | 2020-11-30 | 2023-02-28 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| CN116981685A (zh) * | 2020-12-03 | 2023-10-31 | 世纪治疗股份有限公司 | 基因工程化细胞及其用途 |
| EP4255922A1 (en) | 2020-12-03 | 2023-10-11 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
| WO2022144632A1 (en) | 2020-12-30 | 2022-07-07 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into nk cells |
| CN115786271B (zh) * | 2021-01-12 | 2025-07-22 | 上海雅科生物科技有限公司 | 靶向cd7的工程化免疫细胞、嵌合抗原受体、cd7阻断分子及应用 |
| CN112778427B (zh) * | 2021-01-29 | 2022-03-15 | 武汉思安医疗技术有限公司 | 双特异性cs1-bcma car-t细胞及其应用 |
| US20220267423A1 (en) * | 2021-02-22 | 2022-08-25 | IgGenix, Inc. | Ige antibodies cross-reactive to allergens and tumor antigens |
| CN112698037B (zh) * | 2021-03-25 | 2021-06-25 | 北京积水潭医院 | 一种检测多发性骨髓瘤治疗效果的抗体组合物及其试剂盒和应用 |
| WO2022234976A1 (ko) * | 2021-05-04 | 2022-11-10 | 주식회사 이뮤노로지컬디자이닝랩 | 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도 |
| KR102671411B1 (ko) * | 2021-05-11 | 2024-06-04 | 진화섭 | Baff 세포외 도메인을 포함하는 키메릭 항원 수용체 및 이의 용도 |
| CN115340610A (zh) * | 2021-05-12 | 2022-11-15 | 珠海市丽珠单抗生物技术有限公司 | 双特异性car t细胞及其应用 |
| CN113501884B (zh) * | 2021-06-30 | 2022-03-22 | 徐州医科大学 | 靶向B7H3的全人源嵌合抗原受体、iNKT细胞及其用途 |
| CN113549158B (zh) * | 2021-07-19 | 2022-10-21 | 广州百暨基因科技有限公司 | 包含突变型il15以及嵌合抗原受体的融合蛋白 |
| EP4376876A1 (en) * | 2021-07-26 | 2024-06-05 | Kite Pharma, Inc. | Split chimeric antigen receptors and methods of use |
| US20250222102A1 (en) * | 2021-08-24 | 2025-07-10 | City Of Hope | Nk cells expressing il-15 and checkpoint inhibitors for the treatment of cancer |
| KR20230032557A (ko) * | 2021-08-31 | 2023-03-07 | 주식회사 이뮤노로지컬디자이닝랩 | Baff 세포외 도메인을 포함하는 재조합 단백질 및 이를 유효성분으로 포함하는 암의 치료용 약학적 조성물 |
| CA3231445A1 (en) * | 2021-09-16 | 2023-03-23 | Martin Schroeder | B7-h3 targeting fusion proteins and methods of use thereof |
| WO2023091954A2 (en) * | 2021-11-19 | 2023-05-25 | The Trustees Of The University Of Pennsylvania | Engineered pan-leukocyte antigen cd45 to facilitate car t cell therapy |
| US20230210900A1 (en) * | 2022-01-04 | 2023-07-06 | Kyverna Therapeutics, Inc. | Methods for treating autoimmune diseases |
| EP4272754A1 (en) | 2022-05-04 | 2023-11-08 | Universitätsklinikum Hamburg-Eppendorf | Method for producing cells expressing a chimeric antigen receptor (car) |
| EP4522751A1 (en) * | 2022-05-10 | 2025-03-19 | Miltenyi Biotec B.V. & Co. KG | Compositions comprising il-15, il-15 receptor alpha and the intracellular signaling domain of cd2 for immune cell therapy |
| WO2024026455A2 (en) * | 2022-07-29 | 2024-02-01 | Shoreline Biosciences, Inc. | Methods and compositions for generating chimeric antigen receptor-monocytes/macrophages |
| EP4487868A1 (en) | 2023-07-06 | 2025-01-08 | Universitätsklinikum Hamburg-Eppendorf | Modified nk cell expressing a chimeric antigen receptor |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
| WO2025072372A1 (en) * | 2023-09-26 | 2025-04-03 | The General Hospital Corporation | Car-t cells expressing vegf binding proteins |
| CN117050195B (zh) * | 2023-10-13 | 2023-12-19 | 旭和（天津）医药科技有限公司 | 一种靶向baffr嵌合抗原受体、car-t细胞和应用 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6764681B2 (en) | 1991-10-07 | 2004-07-20 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| JP2003516124A (ja) | 1999-10-15 | 2003-05-13 | ユニバーシティー オブ マサチューセッツ | 標的とした遺伝的干渉の手段としてのｒｎａ干渉経路遺伝子 |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| AU2001275474A1 (en) | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
| US20030147865A1 (en) * | 2002-02-07 | 2003-08-07 | Benoit Salomon | Cell therapy using immunoregulatory T-cells |
| US20080254027A1 (en) | 2002-03-01 | 2008-10-16 | Bernett Matthew J | Optimized CD5 antibodies and methods of using the same |
| EP1539234A4 (en) | 2002-09-05 | 2006-02-15 | Medimmune Inc | METHOD FOR PREVENTING OR TREATING CELL MALIGNITY BY ADMINISTERING CD2 ANTAGONISTS |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| WO2010042654A2 (en) * | 2008-10-07 | 2010-04-15 | The Regents Of The University Of California | Recombinant nell protein production |
| WO2005108415A2 (en) | 2004-04-30 | 2005-11-17 | Biogen Idec Ma Inc. | Membrane associated molecules |
| US20050277587A1 (en) | 2004-06-10 | 2005-12-15 | Academia Sinica | CD7 as biomarker and therapeutic target for psoriasis |
| EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| EP2441846A3 (en) * | 2006-01-09 | 2012-07-25 | The Regents Of the University of California | Immunostimulatory combinations of TNFRSF, TLR, NLR, RHR, purinergic receptor, and cytokine receptor agoinsts for vaccines and tumor immunotherapy |
| CN101501498A (zh) | 2006-06-12 | 2009-08-05 | 森托科尔公司 | 根据rantes代表物水平检测il-16活性和对il-16活性的调节的方法 |
| DK3284825T3 (da) | 2006-11-02 | 2021-05-25 | Biomolecular Holdings Llc | Fremgangsmåder til at fremstille hybride polypeptider med bevægelige dele |
| WO2009091826A2 (en) | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
| JP2012501180A (ja) * | 2008-08-26 | 2012-01-19 | シティ・オブ・ホープ | Ｔ細胞の抗腫瘍エフェクター機能増進のための方法および組成物 |
| EP2389443B1 (en) | 2009-01-23 | 2018-11-14 | Roger Williams Hospital | Retroviral vectors encoding multiple highly homologous non-viral polypeptides and the use of same |
| JP5834004B2 (ja) | 2009-05-13 | 2015-12-16 | ジェンザイム・コーポレーション | ループス治療のための方法および組成物 |
| US20120058082A1 (en) | 2009-05-13 | 2012-03-08 | Genzyme Corporation | Methods and compositions for treatment |
| EP2325322A1 (en) | 2009-11-23 | 2011-05-25 | 4-Antibody AG | Retroviral vector particles and methods for their generation and use |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| EP2651442B1 (en) | 2010-12-14 | 2020-04-22 | University of Maryland, Baltimore | Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer |
| CA2832356C (en) | 2011-04-06 | 2017-12-19 | Sanbio, Inc. | Methods and compositions for modulating peripheral immune function |
| MX356947B (es) | 2011-08-23 | 2018-06-20 | Roche Glycart Ag | Anticuerpos bioespecíficos específicos para antígenos que activan células t y un antígeno tumoral y métodos de uso. |
| TWI681970B (zh) * | 2011-09-30 | 2020-01-11 | 日商中外製藥股份有限公司 | 包含依離子濃度之條件對抗原之結合活性會改變之抗原結合分域、及於pH中性之條件下對FcRn有結合活性之FcRn結合分域、且誘導對標的抗原的免疫反應之抗原結合分子 |
| EP3594245A1 (en) * | 2012-02-13 | 2020-01-15 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| SG11201404285VA (en) | 2012-02-22 | 2014-10-30 | Univ Pennsylvania | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
| TWI619729B (zh) | 2012-04-02 | 2018-04-01 | 再生元醫藥公司 | 抗－ｈｌａ－ｂ*２７抗體及其用途 |
| EP2903637B1 (en) | 2012-10-02 | 2019-06-12 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for immunotherapy |
| US10117896B2 (en) | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| KR102417657B1 (ko) * | 2013-02-06 | 2022-07-07 | 안트로제네시스 코포레이션 | 개선된 특이성을 갖는 변경된 t 림프구 |
| PL3300745T3 (pl) | 2013-02-15 | 2020-03-31 | The Regents Of The University Of California | Chimeryczny receptor antygenowy i sposoby jego zastosowania |
| EP2970426B1 (en) * | 2013-03-15 | 2019-08-28 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| SG11201508805UA (en) * | 2013-05-13 | 2015-11-27 | Cellectis | Cd19 specific chimeric antigen receptor and uses thereof |
| US9629877B2 (en) * | 2013-05-14 | 2017-04-25 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (CAR) T-cells |
| JP6136650B2 (ja) * | 2013-06-28 | 2017-05-31 | ブラザー工業株式会社 | カートリッジ |
| HUE046964T2 (hu) * | 2013-08-08 | 2020-04-28 | Cytune Pharma | Kombinált gyógyászati készítmény |
| MX389160B (es) * | 2013-10-31 | 2025-03-20 | Hutchinson Fred Cancer Res | Células no t efectoras y madre/progenitoras hematopoyéticas modificadas y usos de estas. |
| EP3176185A1 (en) | 2013-11-04 | 2017-06-07 | Glenmark Pharmaceuticals S.A. | Production of t cell retargeting hetero-dimeric immunoglobulins |
| EP3071221A1 (en) | 2013-11-21 | 2016-09-28 | UCL Business Plc. | Cell |
| EP4303229A3 (en) | 2014-01-21 | 2024-04-17 | Novartis AG | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
| WO2015120180A1 (en) * | 2014-02-05 | 2015-08-13 | The University Of Chicago | Chimeric antigen receptors recognizing cancer-specific tn glycopeptide variants |
| KR102157924B1 (ko) | 2014-02-14 | 2020-10-26 | 셀렉티스 | 면역 세포들 및 병리 세포들 둘 다에 존재하는 항원을 타겟팅하기 위하여 조작된 면역치료용 세포들 |
| US10196608B2 (en) * | 2014-02-21 | 2019-02-05 | Cellectis | Method for in situ inhibition of regulatory T cells |
| NZ739448A (en) * | 2014-04-10 | 2019-10-25 | Seattle Children’S Hospital Dba Seattle Children’S Res Institute | Transgene genetic tags and methods of use |
| CA2984484C (en) * | 2014-05-02 | 2024-01-23 | The Trustees Of The University Of Pennsylvania | Compositions and methods of chimeric autoantibody receptor t cells |
| DE112014006656B4 (de) | 2014-05-14 | 2018-05-17 | Carsgen Therapeutics Limited | Nukleinsäure zur Kodierung eines chimären Antigen-Rezeptor-Proteins und T-Lymphozyt zur Expression eines chimären Antigen-Rezeptor-Proteins |
| US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| DK3183268T3 (da) * | 2014-08-19 | 2020-05-11 | Univ Pennsylvania | Behandling af cancer ved anvendelse af en cd123-kimær antigenreceptor |
| KR102615681B1 (ko) | 2014-08-28 | 2023-12-18 | 바이오아트라, 인코퍼레이티드 | 변형된 t 세포에 대한 조건부 활성 키메라 항원 수용체 |
| KR20210149228A (ko) * | 2014-09-17 | 2021-12-08 | 노파르티스 아게 | 입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화 |
| AU2015343013B2 (en) * | 2014-11-05 | 2020-07-16 | Board Of Regents, The University Of Texas System | Gene modified immune effector cells and engineered cells for expansion of immune effector cells |
| KR102376244B1 (ko) | 2014-12-24 | 2022-03-21 | 오토러스 리미티드 | 세포 |
| TW202444897A (zh) * | 2015-06-25 | 2024-11-16 | 美商生物細胞基因治療有限公司 | 嵌合抗原受體(car)、組合物及其使用方法 |
| CN105384825B (zh) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| GB201518817D0 (en) | 2015-10-23 | 2015-12-09 | Autolus Ltd | Cell |
| MY189819A (en) * | 2015-11-27 | 2022-03-10 | Cartherics Pty Ltd | Genetically modified cells and uses thereof |
| US20200281973A1 (en) * | 2016-03-04 | 2020-09-10 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
| GB201610512D0 (en) * | 2016-06-16 | 2016-08-03 | Autolus Ltd | Chimeric antigen receptor |
| CA3039646A1 (en) * | 2016-10-07 | 2018-04-12 | Novartis Ag | Chimeric antigen receptors for the treatment of cancer |
-
2016
- 2016-12-22 US US16/312,769 patent/US20200283534A1/en not_active Abandoned
- 2016-12-22 EP EP16906492.0A patent/EP3474867A4/en active Pending
- 2016-12-22 WO PCT/US2016/068349 patent/WO2017222593A1/en not_active Ceased
- 2016-12-22 JP JP2018567062A patent/JP7114490B2/ja active Active
- 2016-12-22 EP EP23220747.2A patent/EP4353750A3/en not_active Withdrawn
- 2016-12-22 CA CA3029197A patent/CA3029197A1/en active Pending
- 2016-12-22 CN CN201680087034.6A patent/CN109562126A/zh active Pending
-
2017
- 2017-06-21 US US15/538,620 patent/US11820819B2/en active Active
-
2022
- 2022-08-01 US US17/878,339 patent/US20230340113A1/en active Pending
-
2023
- 2023-10-13 US US18/379,708 patent/US20240141041A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019522973A5 (cg-RX-API-DMAC7.html) | ||
| JP2018518974A5 (cg-RX-API-DMAC7.html) | ||
| JP7527049B2 (ja) | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 | |
| Birkholz et al. | Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer | |
| Li et al. | Preclinical and clinical studies of CAR-NK-cell therapies for malignancies | |
| Benmebarek et al. | Killing mechanisms of chimeric antigen receptor (CAR) T cells | |
| Kershaw et al. | Gene-engineered T cells for cancer therapy | |
| JP2017513470A5 (cg-RX-API-DMAC7.html) | ||
| Morgan et al. | Engineering CAR-T cells for improved function against solid tumors | |
| JP2019528769A5 (cg-RX-API-DMAC7.html) | ||
| AU2014407540B2 (en) | Methods of isolating T cells having antigenic specificity for a cancer-specific mutation | |
| Bien et al. | Serum soluble interleukin 2 receptor α in human cancer of adults and children: a review | |
| JP2021019589A5 (cg-RX-API-DMAC7.html) | ||
| CN105175544B (zh) | 一种抗pd-1人源化单克隆抗体及其应用 | |
| JP2017515464A5 (cg-RX-API-DMAC7.html) | ||
| JP2022159548A5 (cg-RX-API-DMAC7.html) | ||
| JP2020533301A5 (cg-RX-API-DMAC7.html) | ||
| JP2019500012A5 (cg-RX-API-DMAC7.html) | ||
| JP2020517259A5 (cg-RX-API-DMAC7.html) | ||
| JP2020513828A5 (cg-RX-API-DMAC7.html) | ||
| RU2015109631A (ru) | Способ и композиции для клеточной иммунотерапии | |
| JP2017522862A5 (cg-RX-API-DMAC7.html) | ||
| JP2018522567A5 (cg-RX-API-DMAC7.html) | ||
| JP2018517415A5 (cg-RX-API-DMAC7.html) | ||
| JP2017529851A5 (cg-RX-API-DMAC7.html) |